Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: Six More Weeks of Volatility?

If you haven’t heard, the groundhog saw his shadow, and if the snowfall on the East and West coasts weren’t enough of an indication, it looks like winter may be with us for awhile still … along with COVID and its variants, which are still a...
Stockhouse Editorial | February 2, 2022 |

A ‘Barrier’ to Better Health

(Click image to play podcast) The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. But is also one of medicine’s great paradoxes – a system designed to protect the most sensitive region of the body bu...
Dave Jackson | September 29, 2020 |

Jayant Bhandari: East Asia Will Be a Post-Pandemic Success

In conversation with Maurice Jackson of Proven and Probable, Jayant Bhandari of Capitalism and Morality offers his take on what the post-COVID-19 world will look like. Maurice Jackson: Joining us for a conversation is Jayant Bhandari, the founder of Capitalism & M...
Streetwise Reports | June 1, 2020 |

Protagonist's Shares Nearly Double After Reporting Q1 Earnings and Positive Phase 2 Trial Results

Shares of Protagonist Therapeutics traded higher and reached a new 52-week high price after the company released Q1/20 financial results and positive data from its Phase 2 study of PTG-300 in patients with polycythemia vera, a type of blood cancer. After U.S...
Streetwise Reports | May 11, 2020 |

A Tale of Two Markets

"It was the best of times, it was the worst of times, it was the age of wisdom, it was the age of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the season of Light, it was the season of Darkness, it was the spring of hope, it was the win...
Streetwise Reports | March 31, 2020 |

EV predictions show strained metals supply

One of the most prevalent current trends concerning mined commodities is the shift, driven by the effort to reduce our carbon footprint, is towards the electrification of the global transportation system. Electrification is part of the solution to averting further glo...
Richard (Rick) Mills | January 29, 2020 |

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...
Streetwise Reports | January 13, 2020 |

NewLink Genetics Shares Shoot Higher after FDA Ebola Vaccine Approval

Shares of NewLink Genetics got a boost today after the firm reported that the FDA approved its ERVEBO V920 vaccine used in the treatment of Zaire Ebola virus. The company's shares set a new 52-week high price in mid-morning trading. This morning after the U.S. markets...
Streetwise Reports | December 23, 2019 |

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...
Streetwise Reports | November 27, 2019 |

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...
Streetwise Reports | September 27, 2019 |
1 2